Following the shortage of ibuprofen, acetaminophen, diclofenac sodium and other antipyretic drugs, as well as Lihua Qingwen, propyl bulb (intravenous human immunoglobulin, also known as intravenous human blood gamma globulin) is also on the list of hot searches. It is reported that the recent market price of C ball soared, some places were fried to 1500 yuan/bottle.
What's the C-ball that's being robbed?
Human immunoglobulin is the main substance of the body's immune response to foreign antigens. As an immunomodulatory agent, low dose has immune substitution and immune enhancement effects, high dose has anti-inflammatory activities and immune regulation functions. C sphere is a blood product prepared with special separation and purification technology from healthy human plasma. It is a mixture of different IgG molecules, including IgG, IgA, IgM, IgD and IgE, which has dual therapeutic effects of immune replacement and immune regulation.
The indications of proglobulin include: (1) primary immunoglobulin deficiency, such as X-interlocking hypoimmunoglobulinemia, common variant immunodeficiency, deficiency of immunoglobulin G subtype, etc. (2) secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc.; (3) autoimmune diseases, such as essential thrombocytopenic purpura, Kawasaki disease, etc.
With the aging of the population, the change of disease spectrum and the improvement of clinical awareness, the market demand of C bulb is rising. China has adopted a batch issuance system for biological products. According to the China Business Information Network, the number of batch issuance of C ball has been steadily increasing in recent years, from 10.51 million in 2018 to 13.39 million in 2021, and is expected to increase to 15.31 million in 2023.
In addition, the limits of the use of the probulb indication medical insurance have been further expanded, from the severe viral infection and work-related injury insurance in children in 2009 to primary immunoglobulin deficiency, neonatal sepsis, severe primary immune thrombocytopenia, Kawasaki disease, systemic myasthenia gravis, acute Guillen Barre syndrome, etc.
At present, our country propyl ball market competition is intense, a number of enterprises get production approval.
According to the Qianzhan Industry Research Institute; From 2011 to 2020, the enterprises with cumulative approval ratio of more than 10% mainly include Tiantan Biology, Shanghai Raishi, Taibang Biology and Hualan Biology, accounting for nearly 58% in total. Among them, the batch issuance share of Tiantan Biological accounted for 17%, Shanghai Lysi's share accounted for 15%, Taibang Biological accounted for 14%, Hualan Biological accounted for 12%. However, in 2020, the proportion of Tiantan organisms in China's propyl bulb market was the largest, about 24.1%. Shanghai Lux followed with 16.9 percent. Tybon Bio ranked third with 13.2 percent.
Can C Ball treat the New Crown?
Propyl balls do play an important role in the treatment of COVID-19 infections, but there is no need to stock up.
In a study published in the Lancet, 27 percent of 99 patients diagnosed with 2019-nCoV pneumonia at Wuhan Yintintan Hospital received intravenous propyl therapy. The National Health Commission issued the Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol (Trial version 7), which also proposed that for severe and critical cases of children, propyl bulb can be considered as appropriate. The Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol (Trial Version 9) states that intravenous administration of human immunoglobulin for COVID-19 at the early stage of the disease course should be used in patients with high-risk factors, high viral load, and rapid disease progression.
But as a foreign protein, blind injection of propyl bulb sometimes interferes with the formation of autoantibodies, resulting in the establishment of autoimmunity. Also, as a blood product, propyl balls are prone to allergic reactions during infusion, which can be life-threatening in severe cases.
At present, ordinary propidium is abused in the treatment of COVID-19 infection. The public should pay attention to avoid blindly following the trend of storage, which may lead to the failure of patients in real need to buy propidium.
More importantly, the human immunoglobulin for intravenous injection mentioned in the ninth edition of the Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol is different from that for routine intravenous injection. It is a specific novel coronavirus immunoglobulin, which contains a large number of anti-coronavirus antibodies in addition to the original human blood IgG antibodies.
At present, human immunoglobulin is still under development for intravenous injection of COVID-19 in China. In September 2021, Tiantan Biological's "human immunoglobulin for intravenous injection of COVID-19" was approved for clinical use in China. It is reported that the drug is a specific intravenous human immunoglobulin containing highly effective SARS-CoV-2 neutralizing antibody prepared from the plasma of healthy people immunized with approved Chinese biological novel coronavirus inactivated vaccine by purifying and isolating ethanol protein at low temperature and by virus inactivation and removal.
conclusion
Recently, the novel coronavirus has been rampant and multiple strains are circulating. Recently, the US Centers for Disease Control and Prevention announced that 40.5% of the current COVID-19 infections in the US are caused by the highly infectious XBB.1.5 strain of the Omicrone subtype, which mainly attacks the cardiovascular and cerebrovascular systems and digestive systems, and is prone to loose bowels. This makes montmorillonite powder and other antidiarrheal drugs popular online and offline, many out of stock.
The transformation of the national epidemic prevention policy is bound to lead to wave after wave of COVID-19 infection peaks. Coupled with the continuous emergence of new variants of COVID-19, people are advised to take good personal protection while rationally storing drugs, rather than blindly following the trend.
